glp 1 shortage tracker Ro launches GLP-1 supply to help patients navigate shortages GLP-1 Injection Tracker

On 7 April, the FDA published several warning letters, including a batch to companies that the agency said are marketing GLP-1 products, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) products, and triple agonist (GLP-1/GIP/glucagon) products without regulatory approval

some have shown slowed progression of diabetic kidney disease

Diabetes is a significant health problem and one of the astounding challenges for healthcare systems all over Germany

However, if any severe symptoms are experienced, such as significant upper abdominal pain with nausea and vomiting, we recommend urgent evaluation given the possibility of pancreatitis or other more acute conditions